tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Resmed (RMD) and Sarepta Therapeutics (SRPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGNResearch Report), Resmed (RMDResearch Report) and Sarepta Therapeutics (SRPTResearch Report) with bullish sentiments.

Amgen (AMGN)

In a report issued on January 27, Jay Olson from Oppenheimer maintained a Buy rating on Amgen, with a price target of $312.00. The company’s shares closed last Friday at $253.65.

According to TipRanks.com, Olson is a 4-star analyst with an average return of 4.9% and a 39.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Ayala Pharmaceuticals, and Intellia Therapeutics.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $265.67, representing a 4.2% upside. In a report issued on January 19, Piper Sandler also maintained a Buy rating on the stock with a $293.00 price target.

See the top stocks recommended by analysts >>

Resmed (RMD)

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Resmed on January 27 and set a price target of $275.00. The company’s shares closed last Friday at $224.59.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 5.6% and a 52.4% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Butterfly Network, and Nyxoah.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $261.50 average price target, implying an 11.0% upside from current levels. In a report issued on January 17, J.P. Morgan also upgraded the stock to Buy with a $245.00 price target.

Sarepta Therapeutics (SRPT)

In a report issued on January 27, Hartaj Singh from Oppenheimer maintained a Buy rating on Sarepta Therapeutics, with a price target of $150.00. The company’s shares closed last Friday at $122.89, close to its 52-week high of $134.08.

According to TipRanks.com, Singh is a 5-star analyst with an average return of 14.0% and a 45.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, United Therapeutics, and Spruce Biosciences.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $149.27, implying a 19.9% upside from current levels. In a report issued on January 13, RBC Capital also maintained a Buy rating on the stock with a $195.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles